Cargando…
DPP4 as a Potential Candidate in Cardiovascular Disease
The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe...
Autores principales: | Chen, Si-Yu, Kong, Xiang-Quan, Zhang, Ke-Fan, Luo, Shuai, Wang, Feng, Zhang, Jun-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488155/ https://www.ncbi.nlm.nih.gov/pubmed/36147690 http://dx.doi.org/10.2147/JIR.S380285 |
Ejemplares similares
-
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021) -
DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
por: Zhang, Jianqiang, et al.
Publicado: (2019) -
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022) -
The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
por: Du, Hengzhi, et al.
Publicado: (2020) -
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
por: Schuetz, Charles Andy, et al.
Publicado: (2015)